These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34791107)

  • 1. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
    Baraliakos X; Kruse S; Auteri SE; de Peyrecave N; Nurminen T; Kumke T; Hoepken B; Braun J
    Rheumatology (Oxford); 2022 Jul; 61(7):2875-2885. PubMed ID: 34791107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
    van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
    Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
    Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
    Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
    Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
    Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
    Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
    Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
    Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
    van der Heijde D; Gensler LS; Maksymowych WP; Landewé R; Rudwaleit M; Bauer L; Kumke T; Kim M; Auteri SE; Hoepken B; Deodhar A
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
    Braun J; Baraliakos X; Hermann KG; Landewé R; Machado PM; Maksymowych WP; Davies O; Hoepken B; Nurminen T; Stach C; van der Heijde D
    RMD Open; 2017; 3(1):e000430. PubMed ID: 28848654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
    Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
    Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP; Bolce R; Gallo G; Seem E; Geneus VJ; Sandoval DM; Østergaard M; Tada K; Baraliakos X; Deodhar A; Gensler LS
    Rheumatology (Oxford); 2022 Nov; 61(11):4324-4334. PubMed ID: 35188180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab pegol for treating axial spondyloarthritis.
    Desmarais J; Beier S; Deodhar A
    Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
    van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status.
    Rudwaleit M; Deodhar A; Bauer L; Gensler L; Hoepken B; Kumke T; Auteri SE; Kim M; Maksymowych W
    RMD Open; 2024 May; 10(2):. PubMed ID: 38724259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
    Sieper J; Kivitz A; van Tubergen A; Deodhar A; Coteur G; Woltering F; Landewé R
    Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1475-80. PubMed ID: 25832312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
    Robinson PC; Maksymowych WP; Gensler LS; Hall S; Rudwaleit M; Hoepken B; Bauer L; Kumke T; Kim M; de Peyrecave N; Deodhar A
    ACR Open Rheumatol; 2022 Sep; 4(9):794-801. PubMed ID: 35733363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.